Literature DB >> 8049356

Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies.

F Berenbaum1, G Rajzbaum, B Amor, A Toubert.   

Abstract

Granulocyte macrophage colony stimulating factor (GM-CSF) is one of the main cytokines involved in tissue damage during rheumatoid arthritis (RA). To investigate the expression of the GM-CSF receptor (GM-CSF-R) in the synovial tissue of osteoarthritic (OA) and RA patients, biopsy specimens were obtained ex vivo during therapeutic arthroscopy. A semi-quantitative polymerase chain reaction (PCR) technique was performed using specific primers for the alpha chain of the GM-CSF-R and for beta-actin. The PCR products were analyzed after slot-blotting and hybridization with specific cDNA probes. Both RA (n = 11) and OA (n = 7) samples were positive. No significant overexpression correlating with the clinical or histological disease status of the patients was observed. In conclusion, GM-CSF-R could be detected in the synovial tissue where it can mediate the effects of this cytokine locally produced during RA inflammation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049356

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  17 in total

1.  Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice.

Authors:  I K Campbell; A Bendele; D A Smith; J A Hamilton
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

Review 2.  [New biologics and orally available compounds. What is still in the pipeline?].

Authors:  M Grünke; H Bastian; H Schulze-Koops; G-R Burmester
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

Review 3.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

Review 4.  Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.

Authors:  Chiara Crotti; Elena Agape; Andrea Becciolini; Martina Biggioggero; Ennio Giulio Favalli
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 5.  GM-CSF: An immune modulatory cytokine that can suppress autoimmunity.

Authors:  Palash Bhattacharya; Muthusamy Thiruppathi; Hatem A Elshabrawy; Khaled Alharshawi; Prabhakaran Kumar; Bellur S Prabhakar
Journal:  Cytokine       Date:  2015-06-22       Impact factor: 3.861

Review 6.  Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.

Authors:  Palash Bhattacharya; Isadore Budnick; Medha Singh; Muthusamy Thiruppathi; Khaled Alharshawi; Hatem Elshabrawy; Mark J Holterman; Bellur S Prabhakar
Journal:  J Interferon Cytokine Res       Date:  2015-03-24       Impact factor: 2.607

Review 7.  Emerging cell and cytokine targets in rheumatoid arthritis.

Authors:  Gerd R Burmester; Eugen Feist; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

Review 8.  Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.

Authors:  Andrew D Cook; John A Hamilton
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-01-11       Impact factor: 5.346

9.  Development of acute inflammatory arthritis by granulocyte-macrophage colony-stimulating factor during autologous stem cell transplantation for cryoglobulinemia.

Authors:  Olga Meltem Akay; Cengiz Korkmaz; Zafer Gulbas
Journal:  Rheumatol Int       Date:  2007-04-11       Impact factor: 2.631

10.  Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.

Authors:  Gerd R Burmester; Eugen Feist; Matthew A Sleeman; Bing Wang; Barbara White; Fabio Magrini
Journal:  Ann Rheum Dis       Date:  2011-05-25       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.